{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T00:01:23Z","timestamp":1784678483387,"version":"3.55.0"},"reference-count":68,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T00:00:00Z","timestamp":1779235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T00:00:00Z","timestamp":1784678400000},"content-version":"vor","delay-in-days":63,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001871","name":"Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia","doi-asserted-by":"publisher","award":["PTDC\/CCI-CIF\/4613\/2020"],"award-info":[{"award-number":["PTDC\/CCI-CIF\/4613\/2020"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The increasing prevalence of mental health disorders has been matched with growing psychotropic drug consumption rates around the world. Assessing psychopharmacoepidemiological trends and their determinants is essential to guide medical care delivery and public health policies. However, nation-wide studies on up-to-date consumption patterns are scarce and generally disregard relevant pharmacological, medical, socio-demographic, and economic covariates. Previous studies on the Portuguese case, known for critically high consumption rates of benzodiazepines and antidepressants, are limited to the COVID-19 pre-pandemic period. This study uses the full (electronic) dispensation registry of antidepressants, benzodiazepines and zolpidem, antipsychotics and mood stabilisers in Portugal during the years of 2019 to 2022 to model relevant prescription and consumption patterns prior to, during and after the COVID-19 pandemic. The data reveal an accelerated growth trend in antidepressant consumption since 2020, with a 7.41% annual increase in dispensed defined daily doses and a growing user base (1.7M users, 16.1% of the population), overtaking benzodiazepines and zolpidem as the class with most active users. The total annual expenditure has increased 14M\u20ac between 2020 and 2022 (nearly 2M\u20ac in public copayment), notwithstanding price drops in diverse antipsychotic drugs.<\/jats:p>","DOI":"10.1038\/s41598-026-50987-0","type":"journal-article","created":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T04:08:20Z","timestamp":1779250100000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Patterns of psychotropic drug dispensation in Portugal amidst the COVID-19 pandemic and beyond"],"prefix":"10.1038","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7468-4519","authenticated-orcid":false,"given":"David","family":"Belchior","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2718-9758","authenticated-orcid":false,"given":"Lu\u00eds","family":"Madeira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3993-0171","authenticated-orcid":false,"given":"Rui","family":"Henriques","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,20]]},"reference":[{"key":"50987_CR1","unstructured":"Eurofound. Share of adults at risk of depression in 2020\u201322, Living, working and COVID-19 e-survey. https:\/\/stat.link\/qvcu7m."},{"key":"50987_CR2","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1016\/S2215-0366(24)00222-0","volume":"11","author":"The Lancet Psychiatry","year":"2024","unstructured":"The Lancet Psychiatry. Global burden of disease 2021: mental health messages. The Lancet Psychiatry 11, 573. https:\/\/doi.org\/10.1016\/S2215-0366(24)00222-0 (2024).","journal-title":"The Lancet Psychiatry"},{"key":"50987_CR3","unstructured":"Institute of Health Metrics and Evaluation. Global Health Data Exchange. https:\/\/vizhub.healthdata.org\/gbd-results\/ (2019) ."},{"key":"50987_CR4","unstructured":"OECD. Consumption of medicines for selected chronic conditions, 2011, 2019 and 2021 (or nearest years). https:\/\/www.oecd-ilibrary.org\/content\/component\/f11c6179-en (2023)."},{"key":"50987_CR5","doi-asserted-by":"publisher","first-page":"264","DOI":"10.20344\/amp.18680","volume":"36","author":"S Gomes","year":"2023","unstructured":"Gomes, S. et al. Prescri\u00e7\u00e3o de benzodiazepinas e outros sedativos na administra\u00e7\u00e3o regional de sa\u00fade de lisboa e vale do tejo de 2013 a 2020: Um estudo retrospetivo. Acta Med. Port. 36, 264\u2013274 (2023).","journal-title":"Acta Med. Port."},{"key":"50987_CR6","unstructured":"OECD & Observatory, E. Health at a Glance 2023 (2023)."},{"key":"50987_CR7","doi-asserted-by":"publisher","first-page":"6912","DOI":"10.1038\/s41598-023-33765-0","volume":"13","author":"L Madeira","year":"2023","unstructured":"Madeira, L., Queiroz, G. & Henriques, R. Prepandemic psychotropic drug status in Portugal: a nationwide pharmacoepidemiological profile. Sci. Rep. 13, 6912 (2023).","journal-title":"Sci. Rep."},{"key":"50987_CR8","doi-asserted-by":"crossref","unstructured":"Vuki\u0107evi\u0107, T., Dragani\u0107, P., \u0160kribulja, M., Puljak, L. & Do\u0161enovi\u0107, S. Consumption of psychotropic drugs in Croatia before and during the COVID-19 pandemic: a 10-year longitudinal study (2012\u20132021). Soc. Psychiatry Psychiatric Epidemiol. 1\u201313 (2023).","DOI":"10.1007\/s00127-023-02574-1"},{"key":"50987_CR9","doi-asserted-by":"publisher","first-page":"1020023","DOI":"10.3389\/fpsyt.2022.1020023","volume":"13","author":"P Benistand","year":"2022","unstructured":"Benistand, P. et al. Effect of the COVID-19 pandemic on the psychotropic drug consumption. Front. Psych. 13, 1020023 (2022).","journal-title":"Front. Psych."},{"key":"50987_CR10","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.euroneuro.2023.04.004","volume":"73","author":"A Laurin","year":"2023","unstructured":"Laurin, A. et al. Psychotropic drugs consumption during 2020 COVID-19 pandemic and lockdowns: evidence of a surprising resilience of the drugs delivery system in France. Eur. Neuropsychopharmacol. 73, 48\u201361 (2023).","journal-title":"Eur. Neuropsychopharmacol."},{"key":"50987_CR11","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1186\/s12889-023-15360-0","volume":"23","author":"MLN Garc\u00eda","year":"2023","unstructured":"Garc\u00eda, M. L. N., Mart\u00ednez, P. F., Bret\u00f3n, E. F., Mart\u00ednez Alfonso, M. M. & Gil, P. S. Psychotropic consumption before and during COVID-19 in Asturias, Spain. BMC Public Health 23, 494 (2023).","journal-title":"BMC Public Health"},{"key":"50987_CR12","doi-asserted-by":"publisher","first-page":"1131357","DOI":"10.3389\/fphar.2023.1131357","volume":"14","author":"FdS Del Fiol","year":"2023","unstructured":"Del Fiol, F. d. S., Bergamaschi, C. d. C. & Barberato-Filho, S. Sales trends of psychotropic drugs in the COVID-19 pandemic: a national database study in Brazil. Front. Pharmacol. 14, 1131357 (2023).","journal-title":"Front. Pharmacol."},{"key":"50987_CR13","doi-asserted-by":"publisher","first-page":"12124","DOI":"10.1038\/s41598-025-96037-z","volume":"15","author":"M Oscoz-Irurozqui","year":"2025","unstructured":"Oscoz-Irurozqui, M., Villani, L., Martinelli, S., Ricciardi, W. & Gualano, M. R. Trend analysis of antidepressant consumption in Italy from 2008 to 2022 in a public health perspective. Sci. Rep. 15, 12124 (2025).","journal-title":"Sci. Rep."},{"key":"50987_CR14","doi-asserted-by":"publisher","DOI":"10.1192\/bjo.2025.10073","volume":"11","author":"H Newman","year":"2025","unstructured":"Newman, H., Branford, D., Laugharne, R., Byng, R. & Shankar, R. Twenty-five year trend in antipsychotic medication prescribing in England: challenges and opportunities. BJPsych Open 11, e151 (2025).","journal-title":"BJPsych Open"},{"key":"50987_CR15","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.3390\/ijerph13121177","volume":"13","author":"P Carrasco-Garrido","year":"2016","unstructured":"Carrasco-Garrido, P. et al. Time trend in psychotropic medication use in Spain: a nationwide population-based study. Int. J. Environ. Res. Public Health 13, 1177 (2016).","journal-title":"Int. J. Environ. Res. Public Health"},{"key":"50987_CR16","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1111\/j.1600-0447.1996.tb09881.x","volume":"94","author":"J De Wilde","year":"1996","unstructured":"De Wilde, J., Geerts, S., Van Dorpe, J., Bruhwyler, J. & G\u00e9czy, J. A double-blind randomized placebo-controlled study of the efficacy and safety of pirlindole, a reversible monoamine oxidase a inhibitor, in the treatment of depression. Acta Psychiatr. Scand. 94, 404\u2013410 (1996).","journal-title":"Acta Psychiatr. Scand."},{"key":"50987_CR17","doi-asserted-by":"publisher","first-page":"61","DOI":"10.2165\/11586690-000000000-00000","volume":"31","author":"A Macedo","year":"2011","unstructured":"Macedo, A., Leiria, E. & Filipe, A. Pirlindole in the treatment of depression: a meta-analysis. Clin. Drug Investig. 31, 61\u201371 (2011).","journal-title":"Clin. Drug Investig."},{"key":"50987_CR18","unstructured":"Instituto Nacional de Estat\u00edstica. Instituto Nacional de Estat\u00edstica. https:\/\/www.ine.pt\/."},{"key":"50987_CR19","doi-asserted-by":"crossref","unstructured":"Sarangi, A., McMahon, T. & Gude, J. Benzodiazepine misuse: an epidemic within a pandemic. Cureus13 (2021).","DOI":"10.7759\/cureus.15816"},{"key":"50987_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2019.05.008","volume":"163","author":"MV Seeman","year":"2020","unstructured":"Seeman, M. V. Men and women respond differently to antipsychotic drugs. Neuropharmacology 163, 107631 (2020).","journal-title":"Neuropharmacology"},{"key":"50987_CR21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12877-021-02213-x","volume":"21","author":"A Luka\u010di\u0161inov\u00e1","year":"2021","unstructured":"Luka\u010di\u0161inov\u00e1, A. et al. The prevalence and prescribing patterns of benzodiazepines and Z-drugs in older nursing home residents in different European countries and Israel: retrospective results from the EU SHELTER study. BMC Geriatr. 21, 1\u201316 (2021).","journal-title":"BMC Geriatr."},{"key":"50987_CR22","unstructured":"HSBC - Health Behaviour in School-aged Children. A sa\u00fade dos adolescentes portugueses em contexto de pandemia \u2013 dados nacionais 2022. https:\/\/hbsc.org\/portuguese-adolescents-mental-health-and-well-being-decline-hbsc-study-reveals."},{"key":"50987_CR23","doi-asserted-by":"publisher","DOI":"10.1111\/jsr.14035","volume":"32","author":"D Riemann","year":"2023","unstructured":"Riemann, D. et al. The European insomnia guideline: an update on the diagnosis and treatment of insomnia 2023. J. Sleep Res. 32, e14035 (2023).","journal-title":"J. Sleep Res."},{"key":"50987_CR24","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1097\/ADM.0000000000000350","volume":"12","author":"N Ait-Daoud","year":"2018","unstructured":"Ait-Daoud, N., Hamby, A. S., Sharma, S. & Blevins, D. A review of alprazolam use, misuse, and withdrawal. J. Addict. Med. 12, 4\u201310 (2018).","journal-title":"J. Addict. Med."},{"key":"50987_CR25","doi-asserted-by":"publisher","first-page":"1212028","DOI":"10.3389\/fpsyt.2023.1212028","volume":"14","author":"M Soyka","year":"2023","unstructured":"Soyka, M. et al. Long-term use of benzodiazepines in chronic insomnia: a European perspective. Front. Psych. 14, 1212028 (2023).","journal-title":"Front. Psych."},{"key":"50987_CR26","doi-asserted-by":"crossref","unstructured":"Brandt, J. et al. Prescribing and deprescribing guidance for benzodiazepine and benzodiazepine receptor agonist use in adults with depression, anxiety, and insomnia: an international scoping review. EClinicalMedicine70 (2024).","DOI":"10.1016\/j.eclinm.2024.102507"},{"key":"50987_CR27","doi-asserted-by":"publisher","first-page":"e2459883","DOI":"10.1001\/jamanetworkopen.2024.59883","volume":"8","author":"V Shapoval","year":"2025","unstructured":"Shapoval, V. et al. Barriers to deprescribing benzodiazepines in older adults in a survey of European physicians. JAMA Netw. Open 8, e2459883\u2013e2459883 (2025).","journal-title":"JAMA Netw. Open"},{"key":"50987_CR28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s40120-014-0016-7","volume":"3","author":"H Fernandes","year":"2014","unstructured":"Fernandes, H. & Moreira, R. Mexazolam: clinical efficacy and tolerability in the treatment of anxiety. Neurol. Therapy 3, 1\u201314 (2014).","journal-title":"Neurol. Therapy"},{"key":"50987_CR29","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1002\/hup.1074","volume":"25","author":"B Dell\u2019Osso","year":"2010","unstructured":"Dell\u2019Osso, B., Buoli, M., Baldwin, D. S. & Altamura, A. C. Serotonin norepinephrine reuptake inhibitors (SNRIs) in anxiety disorders: a comprehensive review of their clinical efficacy. Hum. Psychopharmacol. Clin. Exp. 25, 17\u201329 (2010).","journal-title":"Hum. Psychopharmacol. Clin. Exp."},{"key":"50987_CR30","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1002\/da.22854","volume":"36","author":"E Jakubovski","year":"2019","unstructured":"Jakubovski, E., Johnson, J. A., Nasir, M., M\u00fcller-Vahl, K. & Bloch, M. H. Systematic review and meta-analysis: Dose-response curve of SSRIs and SNRIs in anxiety disorders. Depress. Anxiety 36, 198\u2013212 (2019).","journal-title":"Depress. Anxiety"},{"key":"50987_CR31","doi-asserted-by":"crossref","unstructured":"De Bandt, D., Haile, S. R., Devillers, L., Bourrion, B. & Menges, D. Prescriptions of antidepressants and anxiolytics in France 2012\u20132022 and changes with the COVID-19 pandemic: interrupted time series analysis. BMJ Mental Health27 (2024).","DOI":"10.1136\/bmjment-2024-301026"},{"key":"50987_CR32","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1097\/HRP.0000000000000230","volume":"28","author":"JS Hyde","year":"2020","unstructured":"Hyde, J. S. & Mezulis, A. H. Gender differences in depression: biological, affective, cognitive, and sociocultural factors. Harv. Rev. Psychiatry 28, 4\u201313 (2020).","journal-title":"Harv. Rev. Psychiatry"},{"key":"50987_CR33","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1177\/1557988315619469","volume":"12","author":"L Lynch","year":"2018","unstructured":"Lynch, L., Long, M. & Moorhead, A. Young men, help-seeking, and mental health services: exploring barriers and solutions. Am. J. Mens Health 12, 138\u2013149 (2018).","journal-title":"Am. J. Mens Health"},{"key":"50987_CR34","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1093\/ageing\/afaa286","volume":"50","author":"N Batelaan","year":"2021","unstructured":"Batelaan, N., Scholten, W., Rhebergen, D. & Van Balkom, A. Why we need to evaluate long-term antidepressant use in older patients with depression. Age Ageing 50, 690\u2013692 (2021).","journal-title":"Age Ageing"},{"key":"50987_CR35","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1176\/ajp.151.7.1069","volume":"151","author":"AA Nierenberg","year":"1994","unstructured":"Nierenberg, A. A., Adler, L. A., Peselow, E., Zornberg, G. & Rosenthal, M. Trazodone for antidepressant-associated insomnia. Am. J. Psychiatry 151, 1069\u20131072 (1994).","journal-title":"Am. J. Psychiatry"},{"key":"50987_CR36","first-page":"24","volume":"14","author":"KY Jaffer","year":"2017","unstructured":"Jaffer, K. Y. et al. Trazodone for insomnia: a systematic review. Innov. Clin. Neurosci. 14, 24 (2017).","journal-title":"Innov. Clin. Neurosci."},{"key":"50987_CR37","doi-asserted-by":"publisher","first-page":"1737113","DOI":"10.3389\/fphar.2026.1737113","volume":"17","author":"S Chokkakula","year":"2026","unstructured":"Chokkakula, S. et al. The post-marketing safety of venlafaxine: a real-world two-decade pharmacovigilance study using the FAERS database. Front. Pharmacol. 17, 1737113 (2026).","journal-title":"Front. Pharmacol."},{"key":"50987_CR38","unstructured":"INFARMED - Autoridade Nacional do Medicamento e Produtos de Sa\u00fade. Sistema de Pre\u00e7os de Refer\u00eancia. https:\/\/www.infarmed.pt\/web\/infarmed\/entidades\/medicamentos-uso-humano\/avaliacao-tecnologias-saude\/avaliacao-terapeutica-e-economica\/sistema-de-precos-de-referencia."},{"key":"50987_CR39","unstructured":"National Institute for Health and Care Excellence (NICE). Depression in adults: treatment and management (NG222). London, UK. https:\/\/www.nice.org.uk\/guidance\/ng222. Published 29 June 2022; last reviewed 19 September 2024 (2022)."},{"key":"50987_CR40","first-page":"257","volume":"33","author":"A Mosio\u0142ek","year":"2024","unstructured":"Mosio\u0142ek, A. & Podlecka, M. Pharmacotherapy and psychotherapy in depression-complementarity or exclusion?. Adv. Psychiatry Neurol.\/Post\u0119py Psychiatrii i Neurologii 33, 257\u2013266 (2024).","journal-title":"Adv. Psychiatry Neurol.\/Post\u0119py Psychiatrii i Neurologii"},{"key":"50987_CR41","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1017\/S1041610211000755","volume":"23","author":"R Wetzels","year":"2011","unstructured":"Wetzels, R., Zuidema, S. U., de Jonghe, J. F., Verhey, F. R. & Koopmans, R. Prescribing pattern of psychotropic drugs in nursing home residents with dementia. Int. Psychogeriatr. 23, 1249\u20131259 (2011).","journal-title":"Int. Psychogeriatr."},{"key":"50987_CR42","doi-asserted-by":"crossref","unstructured":"Mok, P. L. et al. Multiple adverse outcomes associated with antipsychotic use in people with dementia: population based matched cohort study. BMJ385 (2024).","DOI":"10.1136\/bmj-2023-076268"},{"key":"50987_CR43","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1097\/CCM.0000000000006251","volume":"52","author":"KL Carayannopoulos","year":"2024","unstructured":"Carayannopoulos, K. L. et al. Antipsychotics in the treatment of delirium in critically ill patients: a systematic review and meta-analysis of randomized controlled trials. Crit. Care Med. 52, 1087\u20131096 (2024).","journal-title":"Crit. Care Med."},{"key":"50987_CR44","doi-asserted-by":"crossref","unstructured":"Burry, L. et al. Antipsychotics for treatment of delirium in hospitalised non-ICU patients. Cochrane Database Syst. Rev. (2018).","DOI":"10.1002\/14651858.CD005594.pub3"},{"key":"50987_CR45","unstructured":"Maglione, M. et al. Off-label use of atypical antipsychotics: an update (2011)."},{"key":"50987_CR46","doi-asserted-by":"crossref","unstructured":"Maneeton, N. et al. Quetiapine monotherapy in acute treatment of generalized anxiety disorder: a systematic review and meta-analysis of randomized controlled trials. Drug Design, Dev. Therapy 259\u2013276 (2016).","DOI":"10.2147\/DDDT.S89485"},{"key":"50987_CR47","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1177\/0269881116681399","volume":"31","author":"J Karsten","year":"2017","unstructured":"Karsten, J., Hagenauw, L. A., Kamphuis, J. & Lancel, M. Low doses of mirtazapine or quetiapine for transient insomnia: a randomised, double-blind, cross-over, placebo-controlled trial. J. Psychopharmacol. 31, 327\u2013337 (2017).","journal-title":"J. Psychopharmacol."},{"key":"50987_CR48","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1016\/j.jad.2015.11.002","volume":"191","author":"TA Ketter","year":"2016","unstructured":"Ketter, T. A., Miller, S., Dell\u2019Osso, B. & Wang, P. W. Treatment of bipolar disorder: review of evidence regarding quetiapine and lithium. J. Affect. Disord. 191, 256\u2013273 (2016).","journal-title":"J. Affect. Disord."},{"key":"50987_CR49","doi-asserted-by":"publisher","first-page":"1729","DOI":"10.1177\/0269881109106900","volume":"24","author":"A Cipriani","year":"2010","unstructured":"Cipriani, A., Rendell, J. & Geddes, J. R. Olanzapine in the long-term treatment of bipolar disorder: a systematic review and meta-analysis. J. Psychopharmacol. 24, 1729\u20131738 (2010).","journal-title":"J. Psychopharmacol."},{"key":"50987_CR50","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1007\/s00134-003-2117-0","volume":"30","author":"YK Skrobik","year":"2004","unstructured":"Skrobik, Y. K., Bergeron, N., Dumont, M. & Gottfried, S. B. Olanzapine vs haloperidol: treating delirium in a critical care setting. Intensive Care Med. 30, 444\u2013449 (2004).","journal-title":"Intensive Care Med."},{"key":"50987_CR51","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.euroneuro.2022.11.008","volume":"67","author":"C-Y Lin","year":"2023","unstructured":"Lin, C.-Y., Chiang, C.-H., Tseng, M.-C.M., Tam, K.-W. & Loh, E.-W. Effects of quetiapine on sleep: a systematic review and meta-analysis of clinical trials. Eur. Neuropsychopharmacol. 67, 22\u201336 (2023).","journal-title":"Eur. Neuropsychopharmacol."},{"key":"50987_CR52","doi-asserted-by":"publisher","DOI":"10.1111\/jsr.14051","volume":"33","author":"C Fauska","year":"2024","unstructured":"Fauska, C. et al. Effects of the antipsychotic quetiapine on sleep and breathing: a review of clinical findings and potential mechanisms. J. Sleep Res. 33, e14051 (2024).","journal-title":"J. Sleep Res."},{"key":"50987_CR53","doi-asserted-by":"publisher","first-page":"286","DOI":"10.3949\/ccjm.88a.20031","volume":"88","author":"V Modesto-Lowe","year":"2021","unstructured":"Modesto-Lowe, V., Harabasz, A. K. & Walker, S. A. Quetiapine for primary insomnia: consider the risks. Clevel. Clin. J. Med. 88, 286\u2013294 (2021).","journal-title":"Clevel. Clin. J. Med."},{"key":"50987_CR54","doi-asserted-by":"crossref","unstructured":"Cinar, B. G. et al. Patterns and indications for quetiapine prescribing in Dutch primary care: a retrospective database study. BJGP Open9 (2025).","DOI":"10.3399\/BJGPO.2024.0219"},{"key":"50987_CR55","volume":"11","author":"C O\u2019Donovan","year":"2020","unstructured":"O\u2019Donovan, C. & Alda, M. Depression preceding diagnosis of bipolar disorder. Front. Psych. 11, 537846 (2020).","journal-title":"Front. Psych."},{"key":"50987_CR56","doi-asserted-by":"publisher","first-page":"3723","DOI":"10.3390\/ijms22073723","volume":"22","author":"L Lucidi","year":"2021","unstructured":"Lucidi, L. et al. Gut microbiota and bipolar disorder: an overview on a novel biomarker for diagnosis and treatment. Int. J. Mol. Sci. 22, 3723 (2021).","journal-title":"Int. J. Mol. Sci."},{"key":"50987_CR57","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/s12991-024-00493-2","volume":"23","author":"AM Kanner","year":"2024","unstructured":"Kanner, A. M. et al. Mood disorders in adults with epilepsy: a review of unrecognized facts and common misconceptions. Ann. Gen. Psychiatry 23, 11 (2024).","journal-title":"Ann. Gen. Psychiatry"},{"key":"50987_CR58","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1111\/bdi.13154","volume":"24","author":"G Schoretsanitis","year":"2022","unstructured":"Schoretsanitis, G. et al. Prevalence of impaired kidney function in patients with long-term lithium treatment: a systematic review and meta-analysis. Bipolar Disord. 24, 264\u2013274 (2022).","journal-title":"Bipolar Disord."},{"key":"50987_CR59","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1111\/ane.13446","volume":"144","author":"D Steinbart","year":"2021","unstructured":"Steinbart, D., Gaus, V., Kowski, A. B. & Holtkamp, M. Valproic acid use in fertile women with genetic generalized epilepsies. Acta Neurol. Scand. 144, 288\u2013295 (2021).","journal-title":"Acta Neurol. Scand."},{"key":"50987_CR60","unstructured":"U.S. Geological Survey. Mineral commodity summaries 2024. Tech. Rep. 2024, U.S. Geological Survey, Reston, VA, USA. https:\/\/pubs.usgs.gov\/periodicals\/mcs2024\/mcs2024.pdf (2024)."},{"key":"50987_CR61","unstructured":"U.S. Geological Survey. Mineral commodity summaries 2025. Tech. Rep. 2025, U.S. Geological Survey, Reston, VA, USA. https:\/\/pubs.usgs.gov\/periodicals\/mcs2025\/mcs2025.pdf (2025)."},{"key":"50987_CR62","unstructured":"International Energy Agency (IEA). Global critical minerals outlook 2024. https:\/\/www.iea.org\/reports\/global-critical-minerals-outlook-2024. Licence: CC BY 4.0 (2024)."},{"key":"50987_CR63","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.seizure.2005.11.005","volume":"15","author":"K Hamandi","year":"2006","unstructured":"Hamandi, K. & Sander, J. W. Pregabalin: a new antiepileptic drug for refractory epilepsy. Seizure 15, 73\u201378 (2006).","journal-title":"Seizure"},{"key":"50987_CR64","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.2146\/ajhp060371","volume":"64","author":"ML Blommel","year":"2007","unstructured":"Blommel, M. L. & Blommel, A. L. Pregabalin: an antiepileptic agent useful for neuropathic pain. Am. J. Health Syst. Pharm. 64, 1475\u20131482 (2007).","journal-title":"Am. J. Health Syst. Pharm."},{"key":"50987_CR65","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2024.104605","volume":"133","author":"AG McNeilage","year":"2024","unstructured":"McNeilage, A. G., Sim, A., Nielsen, S., Murnion, B. & Ashton-James, C. E. Experiences of misuse and symptoms of dependence among people who use gabapentinoids: a qualitative systematic review. Int. J. Drug Policy 133, 104605 (2024).","journal-title":"Int. J. Drug Policy"},{"key":"50987_CR66","doi-asserted-by":"crossref","unstructured":"Soeiro, T., Uras, M., Jouanjus, \u00c9., Lapeyre-Mestre, M. & Micallef, J. High-dose use of pregabalin and Gabapentin in France: a retrospective, population-based cohort study. The Lancet Reg. Health\u2013Eur.57 (2025).","DOI":"10.1016\/j.lanepe.2025.101424"},{"key":"50987_CR67","doi-asserted-by":"publisher","first-page":"723","DOI":"10.4103\/indianjpsychiatry.indianjpsychiatry_307_24","volume":"66","author":"A Ghosh","year":"2024","unstructured":"Ghosh, A. et al. Understanding pregabalin misuse and dependence: Insights from a north Indian addiction treatment center. Indian J. Psych. 66, 723\u2013728 (2024).","journal-title":"Indian J. Psych."},{"key":"50987_CR68","doi-asserted-by":"publisher","first-page":"1511168","DOI":"10.3389\/fpsyt.2025.1511168","volume":"16","author":"Y Luo","year":"2025","unstructured":"Luo, Y. et al. A case report of pregabalin misuse leading to drug dependence. Front. Psych. 16, 1511168 (2025).","journal-title":"Front. Psych."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-50987-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-50987-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-50987-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T23:18:13Z","timestamp":1784675893000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-50987-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,20]]},"references-count":68,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["50987"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-50987-0","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,20]]},"assertion":[{"value":"5 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethical approval for the study, including access to and processing of the full electronic prescription and dispensation registry in Portugal, was given by the Ethics Committee of the\n                      Centro Acad\u00e9mico de Medicina de Lisboa\n                      (CAML) with the reference number 340\/20, which also covers the waiver of informed consent. The authors further declare full compliance with applicable ethical and regulatory standards, including those principles embodied in the Declaration of Helsinki.","order":2,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"22892"}}